Representational image. — APP/FileDear friends, in the year 2029, as we reflect on the past five years, it is highly satisfying to note how much... Pakistan is not a finished product, by any ...

Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, California’s BridgeBio is stepping into the spotlight of the J.P. Morgan ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Request permissions for this article. Department of Cardiology, Heart Centre (A.A.R., K.R., A.H.C., H.B., F.G.), Copenhagen University Hospital–Rigshospitalet ...